WithdrawnPhase 1NCT03998592

Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes

Studying Rheumatic fever

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Butantan Institute
Principal Investigator: Luiza Guilherme, PhD
InCor Heart Institute
Intervention: Streptococcus pyogenes vaccine (50 µg)(biological)
Eligibility: 18-45 years · All sexes
Timeline: 2021 – 2023

Collaborators

InCor - Instituto do Coração - HCFMUSP.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03998592 on ClinicalTrials.gov

Other trials for Rheumatic fever

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06259006
TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children
Starship Child Health, Te Toka Tumai Auckland
RECRUITINGNANCT06400628
Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes
Jimma University

See all trials for Rheumatic fever →

← Back to all trials